The award, named after Andreas Grüntzig, the pioneering German cardiologist who developed the first balloon angioplasty, is the highest honor presented by the Percutaneous Cardiovascular Registry (PCR).
The award, named after Andreas Grüntzig, the pioneering German cardiologist who developed the first balloon angioplasty, is the highest honor presented by the Percutaneous Cardiovascular Registry (PCR).
Key takeaways:
Project combines a wide range of data from more than 2,200 breast cancer patients to help the development of personalised AI-driven tools.
Researchers have developed two dedicated applications to monitor both physical...
Key takeaways:
Project combines a wide range of data from more than 2,200 breast cancer patients to help the development of personalised AI-driven tools.
Researchers have developed two dedicated applications to monitor both physical...
Your heart already has its own built-in bypass system that predicts whether the heart muscle is alive or dead, according to new research from the University of East Anglia and Norfolk and Norwich University Hospital.
A new study reveals...
Your heart already has its own built-in bypass system that predicts whether the heart muscle is alive or dead, according to new research from the University of East Anglia and Norfolk and Norwich University Hospital.
A new study reveals...
The Vertex system leverages the company’s patented Transforming Fixation (TFX) platform technology in a novel catheter system designed to navigate flexibly through the right heart and then stabilize on-demand in the pulmonary arteries for...
The Vertex system leverages the company’s patented Transforming Fixation (TFX) platform technology in a novel catheter system designed to navigate flexibly through the right heart and then stabilize on-demand in the pulmonary arteries for...
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood...
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood...
Eli Lilly and Company announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein...
Eli Lilly and Company announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein...
Boston, MA – NodThera, a clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers of cardiometabolic and neurologic diseases, announced the...
Boston, MA – NodThera, a clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers of cardiometabolic and neurologic diseases, announced the...
BOSTON--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, announced the enrollment of the first patient in its first-in-human (FIH) study for...
BOSTON--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, announced the enrollment of the first patient in its first-in-human (FIH) study for...
DEEPER CORONARY is a first-in-human pilot study designed to evaluate the short-term safety of the investigational coronary Spur Elute System as a primary treatment for coronary ISR.
DEEPER CORONARY is a first-in-human pilot study designed to evaluate the short-term safety of the investigational coronary Spur Elute System as a primary treatment for coronary ISR.
